scholarly journals The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies

2018 ◽  
Vol 34 (1-2) ◽  
pp. 52-60 ◽  
Author(s):  
Megan E. Cavet ◽  
Heleen H. DeCory
2020 ◽  
pp. 112067212094433 ◽  
Author(s):  
Momen Mahmoud Hamdi ◽  
Islam Mahmoud Hamdi

Purpose: To compare between mitomycin C alone, porcine extracellular matrix alone, and combined low dose mitomycin C with porcine extracellular matrix in term of efficacy and safety in phaco-trabeculectomy surgery. Study design: Prospective comparative. Methods: Sixty eyes of 60 patients complaining of primary open angle glaucoma and cataract, undergoing phaco-trabeculectomy, were distributed into three groups: group I: surgery was augmented with mitomycin C, group II with porcine extracellular matrix, and group III with porcine extracellular matrix combined with low dose mitomycin C. Intraocular pressure was evaluated, postoperatively, at day 1, week 1, and 1, 3, 6, 9, and 12 months. Bleb vascularity, pre- and post-operative intraocular pressure lowering medications, success of IOP control and complications were also evaluated. Results: After 12 months, the mean preoperative intraocular pressure (mm Hg) improved from 30.85 ± 4.7, 33.8 ± 4.2, and 31.05 ± 5.4 mm Hg, in groups I, II, and III respectively, to 13.8 ± 4.7 (55.2%), 15.2 ± 4.8 (55%), and 13 ± 4.9 (58.1%) ( p > 0.05). Success of IOP control, postoperative IOP lowering medications and complications were comparable ( p > 0.05). Bleb vascularity was significantly different ( p < 0.05). Conclusion: Mitomycin C, porcine extracellular matrix and their combination are equally effective in phacotrabeculectomy.


Pharmacology ◽  
2006 ◽  
Vol 77 (1) ◽  
pp. 17-24 ◽  
Author(s):  
Juanita Dortch-Carnes ◽  
Karen R.M. Russell

2013 ◽  
Vol 116 ◽  
pp. 247-253 ◽  
Author(s):  
Doreen Schmidl ◽  
Agnes Boltz ◽  
Semira Kaya ◽  
Stefan Palkovits ◽  
Reinhard Told ◽  
...  

2014 ◽  
Vol 43 (1) ◽  
pp. 54-66 ◽  
Author(s):  
Norhafiza Razali ◽  
Renu Agarwal ◽  
Puneet Agarwal ◽  
Sunil Kumar ◽  
Minaketan Tripathy ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Mariana Y. García-Bermúdez ◽  
Kristine K. Freude ◽  
Zaynab A. Mouhammad ◽  
Peter van Wijngaarden ◽  
Keith K. Martin ◽  
...  

Glaucoma is the second leading cause of blindness worldwide, affecting ~80 million people by 2020 (1, 2). The condition is characterized by a progressive loss of retinal ganglion cells (RGCs) and their axons accompanied by visual field loss. The underlying pathophysiology of glaucoma remains elusive. Glaucoma is recognized as a multifactorial disease, and lowering intraocular pressure (IOP) is the only treatment that has been shown to slow the progression of the condition. However, a significant number of glaucoma patients continue to go blind despite intraocular pressure-lowering treatment (2). Thus, the need for alternative treatment strategies is indisputable. Accumulating evidence suggests that glial cells play a significant role in supporting RGC function and that glial dysfunction may contribute to optic nerve disease. Here, we review recent advances in understanding the role of glial cells in the pathophysiology of glaucoma. A particular focus is on the dynamic and essential interactions between glial cells and RGCs and potential therapeutic approaches to glaucoma by targeting glial cells.


2015 ◽  
Vol 56 (11) ◽  
pp. 6558 ◽  
Author(s):  
Francesco Impagnatiello ◽  
Carol B. Toris ◽  
Minerva Batugo ◽  
Ganesh Prasanna ◽  
Valentina Borghi ◽  
...  

2002 ◽  
Vol 18 (1) ◽  
pp. 11-23 ◽  
Author(s):  
Hanna Kotikoski ◽  
Päivi Alajuuma ◽  
Eeva Moilanen ◽  
Pertteli Salmenperä ◽  
Olli Oksala ◽  
...  

2010 ◽  
Vol 5 (6) ◽  
pp. 751-758
Author(s):  
Heikki Vapaatalo ◽  
Hanna Kotikoski ◽  
Olli Oksala

Sign in / Sign up

Export Citation Format

Share Document